Cystic Fibrosis Foundation: FDA Approves Trikafta for 94 Additional Rare CFTR Mutations
December 21, 2024
December 21, 2024
BETHESDA, Maryland, Dec. 21 -- Cystic Fibrosis Foundation issued the following news release on Dec. 20, 2024:
* * *
The U.S. Food and Drug Administration (FDA) today approved the expansion of Trikafta (elexacaftor/tezacaftor/ivacaftor) to people with cystic fibrosis ages 2 and older who have at least one of 94 rare mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
* * *
The approval enables a small number of peop . . .
* * *
The U.S. Food and Drug Administration (FDA) today approved the expansion of Trikafta (elexacaftor/tezacaftor/ivacaftor) to people with cystic fibrosis ages 2 and older who have at least one of 94 rare mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
* * *
The approval enables a small number of peop . . .